{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:46:26Z","timestamp":1762101986487},"reference-count":21,"publisher":"Impact Journals, LLC","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,4]]},"DOI":"10.18632\/oncotarget.15146","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T22:21:23Z","timestamp":1486506083000},"page":"22606-22615","source":"Crossref","is-referenced-by-count":13,"title":["Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors"],"prefix":"10.18632","volume":"8","author":[{"given":"Paavo O.","family":"Pietarinen","sequence":"first","affiliation":[{"name":"Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA"},{"name":"Howard Hughes Medical Institute, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Ayuda-Dur\u00e1n","sequence":"additional","affiliation":[{"name":"Oslo University Hospital, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapnil","family":"Potdar","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heikki","family":"Kuusanm\u00e4ki","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma I.","family":"Andersson","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Mpindi","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tea","family":"Pemovska","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"},{"name":"Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kontro","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[{"name":"Department of Hematology, St Olavs Hospital, Trondheim, Norway"},{"name":"Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA"},{"name":"Howard Hughes Medical Institute, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorrit M.","family":"Enserink","sequence":"additional","affiliation":[{"name":"Oslo University Hospital, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA"},{"name":"Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Kantarjian","year":"2012","journal-title":"Cancer"},{"key":"2","first-page":"2851","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Andersson","year":"2017","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review","volume":"93","author":"Fu","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12234","article-title":"Do we need more drugs for chronic myeloid leukemia?","volume":"263","author":"Helgason","year":"2015","journal-title":"Immunol Rev"},{"key":"5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11899-015-0248-3","article-title":"Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors","volume":"10","author":"O'Hare","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"6","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1038\/bcj.2015.30","article-title":"Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing","volume":"5","author":"Mustjoki","year":"2015","journal-title":"Blood Cancer J"},{"key":"7","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V84.9.2912.2912","article-title":"Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells","volume":"84","author":"Golde","year":"1994","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V84.6.1731.1731","article-title":"Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia","volume":"84","author":"Groffen","year":"1994","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia","volume":"3","author":"Kulesskiy","year":"2013","journal-title":"Cancer Discov"},{"key":"10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"Drexler","year":"2011","journal-title":"J Hematol Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"e83510","DOI":"10.1371\/journal.pone.0083510","article-title":"Inhibition of PI3K\/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2","volume":"8","author":"Quentmeier","year":"2013","journal-title":"PLoS One"},{"key":"12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/cbt.26725","article-title":"Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation","volume":"15","author":"Ohyashiki","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Holyoake","year":"2002","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Druker","year":"2011","journal-title":"J Clin Invest"},{"key":"15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2012.08.006","article-title":"Selective elimination of leukemia stem cells: hitting a moving target","volume":"338","author":"Jamieson","year":"2013","journal-title":"Cancer Lett"},{"key":"16","first-page":"1958","article-title":"The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X","volume":"6","author":"Aulitzky","year":"2000","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Bhatia","year":"2002","journal-title":"Blood"},{"key":"18","first-page":"1853","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Markev\u00e4rn","year":"2017","journal-title":"Leukemia"},{"key":"19","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Kallioniemi","year":"2014","journal-title":"Sci Rep"},{"key":"20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","article-title":"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening","volume":"73","author":"Oh","year":"2013","journal-title":"Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/j.1349-7006.2011.02041.x","article-title":"Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors","volume":"102","author":"Hatake","year":"2011","journal-title":"Cancer Sci"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T04:02:42Z","timestamp":1692676962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":21,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,4,4]]}},"alternative-id":["15146","28186983"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15146","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,7]]}}}